DUBLIN--(BUSINESS WIRE)--The "Anal Fistula Treatment - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
According to the report, the Global Anal Fistula Treatment Market accounted for $549.8 million in 2017 and expected to grow at a CAGR of 4.2% to reach $798.71 million by 2026.
The increase in prevalence of inflammatory bowel diseases is triggering the market growth. However, the high cost associated with the treatments such as cost of surgery & the post-operative treatments and the lack of awareness regarding the condition are hindering the market. The non-surgical procedures for the treatment of anal fistula provide ample opportunities to the market.
By geography, emerging nations such as China, India, and countries in Southeast Asia are likely to add to the growth of the market in Asia Pacific. Initiatives to progress health care infrastructure, growing health care expenditures and trend of medical tourism in these countries are projected to boost the market in Asia Pacific. Moreover, the rise in number of cases are expected to rise in developing countries as compared to developed countries owing to western dietary patterns, increase in use of antibiotics, surge in exposure to pollution, and improvement in hygiene.
Key Topics Covered
1 Executive Summary
2 Preface
3 Market Trend Analysis
4 Porters Five Force Analysis
5 Global Anal Fistula Treatment Market, By Application
6 Global Anal Fistula Treatment Market, By Treatment Type
7 Global Anal Fistula Treatment Market, By End-User
8 Global Anal Fistula Treatment Market, By Geography
9 Key Developments
10 Company Profiling
- Medtronic PLC
- Gem SRL
- Biolitec AG
- W. L. Gore & Associates Inc. (Gore Medical)
- Becton, Dickinson and Company
- TiGenix NV
- Karl Storz SE & Co. KG
- Cook Medical
- Novartis
- Johnson & Johnson
- Bristol Myers
- Mylan
For more information about this report visit https://www.researchandmarkets.com/research/n7dtrr/global_anal?w=4
